INTI — Inhibitor Therapeutics, Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1042418 ·
Last close
$0.08
Market Cap
$13.29M
52W High
$0.12
52W Low
$0.07
ADV30
12,983
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -695,632 | -686,425 | 1,433,363 | 1,290,978 | 3,411,700 |
| Dec 2025 | 0 | — | -1,315,114 | -1,295,365 | 2,511,307 | 2,375,493 | 3,803,219 |
| Sep 2025 | 0 | — | -741,215 | -712,184 | 3,135,167 | 2,976,658 | 3,131,714 |
| Jun 2025 | 0 | — | -695,773 | -659,942 | 3,907,662 | 3,737,903 | 3,192,025 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,231,370
Investing CF
—
Financing CF
$0
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-55,419,594
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-3,426,653
Pretax Income TTM
$-3,300,337
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -3,426,653 | -3,300,337 | 2,511,307 | 3,803,219 | — | -3,231,370 |
| Dec 2024 | 0 | -3,657,409 | -3,339,201 | 5,694,658 | 3,709,618 | — | -3,233,049 |
| Dec 2023 | 0 | -3,404,979 | -3,026,135 | 8,949,155 | 3,665,164 | — | -2,700,312 |
| Dec 2022 | 0 | -657,926 | 12,106,230 | 11,975,124 | 3,678,782 | — | 11,740,598 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ERNA | Ernexa Therapeutics Inc. | $13.33M | $11.43 | — |
| BFRG | BullFrog AI Holdings, Inc. | $13.13M | $0.71 | — |
| MBRX | Moleculin Biotech, Inc. | $13.07M | $2.45 | — |
| HOTH | Hoth Therapeutics, Inc. | $13.55M | $0.71 | — |
| GDTC | CytoMed Therapeutics Ltd | $13.61M | $1.15 | — |
News headlines (Yahoo Finance, 1h cache)
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
2026-03-31 19:44 · Yahoo
Basal Cell Nevus Syndrome Market Growth Accelerates with Novel Therapies and Clinical Developments | DelveInsight
2025-10-27 21:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.